Date clarification: MetLife’s scheduled 2Q26 results date is Wednesday, August 5, 2026—which is today, not tomorrow. This preview is therefore positioned immediately ahead of the release.
MetLife enters 2Q26 with a strong operating backdrop, a relatively favorable year-over-year comparison, and a stock that has already rerated meaningfully. The central question is less whether Met can improve materially from a soft 2Q25 and more whether underwriting, international growth, and capital return can offset a sequentially lower contribution from variable investment income (VII).
The company has already pre-announced 2Q26 pre-tax VII of $220–270 million. That is substantially below the exceptional $518 million reported in 1Q26, but it remains above the $195 million recorded in 2Q25. This disclosure largely frames the quarter: investors will focus on the degree to which core operations and management’s full-year outlook absorb the expected normalization in alternative-investment returns.
Preview stance: constructive on underlying business momentum, but with a higher bar for the stock after its run-up. A simple adjusted-EPS beat may not be sufficient; the market is likely to require reaffirmed 2026 targets, credible back-half VII assumptions, solid Group Benefits margins, and evidence that MIM/PineBridge is progressing from integration to organic growth.
MetLife pre-announced that 2Q26 VII should be approximately $220–270 million pre-tax, versus full-year guidance of approximately $1.6 billion pre-tax.
This matters because VII was an unusually large contributor to the strong first quarter, when it reached $518 million pre-tax, helped by private-equity returns and venture-capital performance. The pre-announced 2Q range implies a sharp sequential decline, although it is still ahead of the $195 million reported in 2Q25.
The arithmetic is important:
That does not make the full-year target unattainable, but it means investors will scrutinize management’s assumptions for private-equity marks, real-estate funds, prepayment fees, and the trajectory of public and private markets through year-end. The crucial call question is whether management reaffirms the $1.6 billion VII outlook without qualification.
Group Benefits was a major source of 1Q strength:
The favorable life result reflected working-age mortality trends, favorable prior-period development, and a light flu season. Management has been clear that it does not extrapolate all of that benefit indefinitely. Meanwhile, dental utilization, disability severity, and paid-family-leave claims were expected to weigh more in the first half, with moderation anticipated in the second half.
What investors should look for:
A solid Group Benefits result would help validate the durability of MetLife’s core U.S. earnings engine. A weaker result would likely prompt concern that 1Q underwriting was unusually favorable rather than sustainably better.
Retirement & Income Solutions generated $451 million of adjusted earnings in 1Q26, up 11% year over year. Results benefited from VII and underwriting, but investors should be focused on the steadier indicators:
Management had expected core spreads to be roughly stable to modestly improved in 2Q as portfolio rotations eased, though a persistently flat yield curve remained a headwind. The report should clarify whether this played out.
Investors should also watch the mix and profitability of new business—not merely headline pension-risk-transfer volume. MetLife has been emphasizing U.K. longevity reinsurance, U.K. funded reinsurance, structured settlements, post-retirement benefits, and retail-annuity reinsurance as capital-efficient adjacencies. These products support the longer-term thesis if they add liabilities at attractive economics without weakening capital flexibility.
Asia posted an outstanding 1Q:
The near-term framework calls for mid-to-high-single-digit Asia sales growth, mid-single-digit AUM growth, and mid-single-digit adjusted-earnings growth. That means 1Q was well above the planned run rate—and investors should expect tougher comparisons and some moderation.
For 2Q, the key is not necessarily another 30%-plus earnings increase. Rather, the market will want to see:
MetLife Investment Management is now a more material part of the equity story following the PineBridge acquisition. In 1Q26, MIM produced:
The first quarter also included about $2 billion of institutional outflows, tied to market moves, normal client allocation activity, and expected post-close integration effects. Management said flows had stabilized late in the quarter and that the pipeline was constructive.
For 2Q, investors should seek evidence on:
MIM does not need to be the largest 2Q earnings driver to support the stock. But it does need to show that the acquisition is becoming an earnings and distribution asset rather than an integration overhang.
| Metric | 2026 framework | 1Q26 read-through | 2Q26 importance |
|---|---|---|---|
| Adjusted EPS | Double-digit growth | +23% YoY | Reaffirmation matters more than a single-quarter beat |
| Adjusted ROE | 15–17% | 17.0% | Sustainably within range |
| Free-cash-flow ratio | 65–75% | Management reaffirmed confidence | Capital-return capacity |
| VII | ~$1.6B pre-tax | $518M pre-tax | 2Q pre-announced at $220–270M |
| Direct expense ratio | 12.1% | 11.9% | Ability to absorb PineBridge costs |
| Corporate & Other loss | $500–700M | $(177)M in 1Q | Watch recurring margins and tax |
| Effective tax rate | 24–26% | 24% in 1Q | Potential EPS swing factor |
| RIS adjusted earnings | $1.6–1.8B | $451M in 1Q | Spreads and new-business economics |
| MIM adjusted earnings | $240–280M | $47M in 1Q | Flows, synergies, margin trajectory |
MetLife’s 2Q25 adjusted earnings were $1.36 billion, or $2.02 per share, pressured by lower investment margins and less favorable underwriting. VII was just $195 million pre-tax, versus the $220–270 million pre-announced for 2Q26.
That creates a reasonable setup for year-over-year adjusted earnings and EPS growth. However, the stock’s performance suggests that much of the broad improvement thesis is no longer overlooked: MET closed at $96.15 on August 4, 2026, up approximately 21.8% from its $78.94 close on December 31, 2025.
As a result, the market reaction will likely hinge on quality and durability:
A favorable outcome would include:
In that scenario, investors could view the lower sequential VII contribution as a known and manageable normalization rather than a deterioration in earnings quality.
The principal risks are:
The most damaging combination would be lower VII and evidence that core underwriting or spreads cannot compensate.
What assumptions underpin the reaffirmation—or change—of the $1.6 billion 2026 VII target?
How much depends on private-equity marks, venture-capital valuations, real-estate funds, and prepayment fees?
How should investors model Group Life mortality and non-medical health claims in the second half?
Are favorable mortality trends becoming structural, or should they be treated as temporary?
What was the 2Q trajectory for RIS core spread excluding VII?
Has asset rotation subsided, and are new-business returns still meeting hurdle rates?
What is the current pace of RIS retained-liability growth and reinsurance inflows?
Is MetLife maintaining selectivity as it expands in annuity and U.K. reinsurance markets?
Did MIM return to net inflows?
What measurable integration synergies, consultant engagement, and cross-selling wins occurred during the quarter?
Are there any changes to the Japan regulatory situation or implications for sales, distribution, expenses, or capital?
How much share repurchase has been completed since the first-quarter update?
With holding-company liquidity previously at the high end of target, investors will want confirmation that capital return remains on track.
MetLife’s 2Q26 release is best viewed as a test of earnings composition. The pre-announced VII range removes one uncertainty but raises the importance of core execution. The company has a credible path to a strong year-over-year quarter because 2Q25 was weak, but the investment case requires more than that: it requires management to demonstrate that its diversified businesses, disciplined expenses, capital management, and growing asset-management platform can sustain double-digit EPS compounding even as alternative-investment income normalizes.
The highest-value signals: full-year VII confidence, Group Benefits margins, RIS core spreads, Asia sales durability, MIM flow trends, and the willingness to continue returning capital.